

ESMO Preceptorship on Practising Oncology: Dealing with Special Strategies, Patient Populations and Toxicities

PROGRAMME

**ESMO
PRECEPTORSHIP**

**LUGANO SWITZERLAND
3-4 OCTOBER 2024**

Co-Chairs

Christina H. Ruhlmann, Denmark
Radu Vidra, Romania

ESMO PRECEPTORSHIP PROGRAMME

PRACTISING ONCOLOGY: DEALING WITH SPECIAL STRATEGIES, PATIENT POPULATIONS AND TOXICITIES

Challenges for Practising Oncologists

Lugano, Switzerland

3-4 October 2024

CO-CHAIRS Christina H. Ruhlmann, Denmark
Radu Vidra, Romania

SPEAKERS Alberto J. Cunquero, Spain
Roberto Ferrara, Italy
Alice Indini, Italy
Gabor Liposits, Denmark
Olivia Pagani, Switzerland
Benedetta Pellegrino, Italy
Lazar Popovic, Serbia
Hendrik van Halteren, The Netherlands

LEARNING OBJECTIVES

- Provide a state-of-the-art overview on evidence-based perioperative strategies in various tumour settings
- Deliver an overview on the management of challenging clinical situations faced by practicing oncologists in daily practice
- Understand the role of immunotherapy in diverse cancer settings – focusing on its application in perioperative strategies and its management in special patient populations
- Foster the ability to manage complex oncological cases – emphasizing the use of multidisciplinary and molecular tumour boards to optimize treatment plans and improve patient outcomes in challenging clinical scenarios

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Thursday, 3 October 2024

| | | |
|----------------------------|--|--|
| 09:00-09:10 10' | Welcome and introduction General overview of learning objectives | Radu Vidra, RO |
| 09:10-10:50 100' | SESSION 1 Perioperative strategies in various tumour settings – lung cancer | Chair: Alberto J. Cunquero, ES |
| 20' | Participants clinical case discussion (2x10') | Faculty |
| 20' | Perioperative strategies in resectable non-small-cell lung cancer | Roberto Ferrara, IT |
| 20' | Immunotherapy for resectable non-small-cell lung cancer: Neo-adjuvant, adjuvant or both? | Alberto J. Cunquero, ES |
| 20' | MTB in the treatment of lung cancer | Roberto Ferrara, IT |
| 20' | Q&A | All |
| 10:50-11:20 Coffee break | | |
| 11:20-13:00 100' | SESSION 2 Perioperative strategies in various tumour settings – gastrointestinal cancers | Chair: Radu Vidra, RO |
| 20' | Participants clinical case discussion (2x10') | Faculty |
| 20' | Gold standard perioperative strategies upper GI cancer: Is there a place for immunotherapy? | Hendrik van Halteren, NL |
| 20' | Gold standard perioperative strategies lower GI cancer: Is there a place for immunotherapy? | Gabor Liposits, DK |
| 20' | The importance of Molecular Tumour Boards (MTB) in defining class of risk and treatment | Radu Vidra, RO |
| 20' | Q&A | All |
| 13:00-14:00 Lunch | | |
| 14:00-15:40 100' | SESSION 3 Perioperative strategies in various tumour settings – skin cancers | Chair: Hendrik van Halteren, NL |
| 20' | Participants clinical case discussion (2x10') | Faculty |
| 20' | Perioperative strategies in melanoma | Christina H. Ruhlmann, DK |
| 20' | Molecular vs Multidisciplinary Tumour Boards in skin cancers | Alberto J. Cunquero, ES |
| 20' | Perioperative strategy non melanoma skin cancers: Immunotherapy, radiotherapy, and surgery | Alice Indini, IT |
| 20' | Q&A | All |
| 15:40-16:10 Coffee break | | |

| 16:10-17:50 100' | SESSION 4 Immunotherapy in special situations – Part I | Chair: Christina H. Ruhlmann, DK |
|-----------------------------|---|---|
| 20' | Participants clinical case discussion (2x10') | Faculty |
| 20' | Cumulative and late toxicity in immunotherapy | Alice Indini, IT |
| 20' | Management of rare IO toxicities | Christina H. Ruhlmann, DK |
| 20' | Immunotherapy in patients with inflammatory/autoimmune comorbidities or after solid organ transplantation | Hendrik van Halteren, NL |
| 20' | Q&A | All |
| 20:00 | Dinner | |

Friday, 4 October 2024

| 09:00-10:40 100' | SESSION 5 Immunotherapy in special situations – Part II | Chair: Alice Indini, IT |
|-----------------------------|--|---|
| 20' | Participants clinical case discussion (2x10') | Faculty |
| 20' | Genetic counselling for long-term survivors and cancer patient's relatives | Benedetta Pellegrino, IT |
| 20' | The MDT in fertility preservation | Olivia Pagani, CH |
| 20' | Immunotherapy in elderly patients: Can we downgrade based on molecular profile? | Gabor Liposits, DK |
| 20' | Q&A | All |
| 10:40-11:10 | Coffee break | |
| 11:10-12:50 100' | SESSION 6 Perioperative strategies in various tumour settings – breast cancer | Chair: Christina H. Ruhlmann, DK |
| 20' | Participants clinical case discussion (2x10') | Faculty |
| 20' | Perioperative strategies in breast cancer | Olivia Pagani, CH |
| 20' | Immunotherapy in neo-adjuvant, adjuvant or both? | Lazar Popovic, RS |
| 20' | MTB in the treatment of breast cancers | Benedetta Pellegrino, IT |
| 20' | Q&A | All |
| 12:50-12:55 5' | Conclusion and farewell | Radu Vidra, RO |
| 12:55-13:55 | Lunch | |

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion